Commerce Bank decreased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 9.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,282 shares of the medical instruments supplier’s stock after selling 1,483 shares during the quarter. Commerce Bank’s holdings in West Pharmaceutical Services were worth $1,374,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Acrospire Investment Management LLC bought a new position in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $113,000. Citigroup Inc. increased its position in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the period. Wolverine Trading LLC bought a new position in West Pharmaceutical Services in the 2nd quarter worth approximately $200,000. Nomura Holdings Inc. bought a new stake in shares of West Pharmaceutical Services during the second quarter valued at approximately $201,000. Finally, Grandfield & Dodd LLC bought a new stake in shares of West Pharmaceutical Services during the third quarter valued at approximately $201,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.truebluetribune.com/2017/11/20/west-pharmaceutical-services-inc-wst-position-decreased-by-commerce-bank-3.html.
WST has been the topic of several recent analyst reports. Jefferies Group LLC raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price target for the company from $96.00 to $115.00 in a research note on Friday, September 15th. BidaskClub downgraded West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Bank of America Corporation downgraded West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 target price for the company. in a research report on Tuesday, October 17th. Wells Fargo & Company upped their price objective on West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, October 27th. Finally, Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $106.00.
West Pharmaceutical Services, Inc. (NYSE WST) opened at $98.96 on Monday. The firm has a market capitalization of $7,348.07, a P/E ratio of 42.65, a PEG ratio of 2.11 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. West Pharmaceutical Services, Inc. has a 52 week low of $77.97 and a 52 week high of $103.36.
West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.14. The company had revenue of $398.20 million for the quarter, compared to analyst estimates of $386.02 million. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.53 earnings per share. research analysts expect that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current year.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.